Phenotypic Screening in CNS Drug Discovery
Phenotypic screening with neuronal cell cultures on micro electrode arrays () is an elegant and efficient way to discover new neuro-active compounds. NeuroProof analyzes sophisticated activity patterns of individual neurons grown in complex neuronal networks of distinct brain tissues. The functional readouts of these electrophysiological fingerprints are monitored to evaluate test compound's effects on neuronal microcircuits.
Deconvolution of these complex activity patterns which are represented as spike trains is crucial and is performed with intelligent pattern recognition methods developed by NeuroProof.
Contrary to target-based screening, the NeuroProof technology assays a multitude of molecular targets and mechanisms. Therefore, actions of molecules on the change of the whole functional phenotype can be assessed. In this way contribution from any unknown, orphan or not targeted receptors are included in the response.
A compound's fingerprint can be compared to the effects of well known compounds. So it is possible to identify those compounds in our database with the most similar action pattern. This similarity analysis can be performed for each concentration of a compound applied within an experiment. Novel compounds in the development process can be compared to compounds on the market to differentiate their individual action profile.
Compound repositioning is one important application of NeuroProof´s phenotypic screening approach.